Hologic, Inc. $HOLX Shares Sold by Integral Health Asset Management LLC

Integral Health Asset Management LLC reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 20.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 100,000 shares of the medical equipment provider’s stock after selling 25,000 shares during the period. Integral Health Asset Management LLC’s holdings in Hologic were worth $6,749,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in HOLX. Winnow Wealth LLC acquired a new position in shares of Hologic during the 3rd quarter valued at about $26,000. Root Financial Partners LLC acquired a new stake in Hologic during the third quarter worth about $27,000. SJS Investment Consulting Inc. raised its holdings in Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 362 shares during the period. Loomis Sayles & Co. L P acquired a new position in shares of Hologic during the 2nd quarter valued at $33,000. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 168.5% during the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a research note on Friday, November 21st. Finally, Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their price target for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $78.42.

Hologic Price Performance

HOLX opened at $75.12 on Friday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average price is $75.13 and its 200 day moving average price is $72.64. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $75.75. The firm has a market cap of $16.77 billion, a price-to-earnings ratio of 31.30, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the business posted $0.87 earnings per share. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.